OCT-1 as a determinant of response to antileukemic treatment

J. R. Engler, T. P. Hughes, D. L. White

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Despite the excellent responses to imatinib therapy observed in patients with chronic phase chronic myeloid leukemia (CP-CML),1 ∼25% of these patients demonstrate primary resistance or suboptimal response. 2 Inadequate inhibition of the kinase activity of BCR-ABL3 due to low intracellular concentrations of imatinib achieved in target leukemic cells has been associated with suboptimal response.4 The organic cation transporter 1 (OCT-1) has been identified as the major active influx pump for imatinib in CML cells,4,5 and has therefore been investigated as a cause of suboptimal response in patients treated with imatinib.

Original languageEnglish
Pages (from-to)608-611
Number of pages4
JournalClinical Pharmacology and Therapeutics
Issue number4
Publication statusPublished or Issued - Apr 2011
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this